Literature DB >> 7612258

The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas.

T Haerslev1, G K Jacobsen, K Zedeler.   

Abstract

Metallothionein (MT) is a low-molecular-weight protein with a high affinity for group II metal ions, especially zinc and copper. MT serves as an intracellular reservoir of these ions, but may also be involved in the detoxification of certain toxic metal ions such as cadmium. In addition, high MT contents might protect tumour cells from alkylating agents and irradiation. The aim of this study was to evaluate the prognostic significance of immunohistochemically detected MT overexpression in patients with primary breast carcinoma: 478 patients with primary breast carcinoma diagnosed during the period 1980-1985 were included. Formalin-fixed and paraffin-embedded tissue was used. Immunoreactivity for MT was found to be independent of the length of formalin fixation if the sections were microwave processed before incubation with the primary antibody. Patients were divided into two groups: those with MT overexpression (more than 10% positive tumour cells) and those with low expression (less than 10% positive tumour cells). MT overexpression was correlated with postmenopausal status, large tumour size, presence of lymph node metastases, high number of mitoses, severe nuclear pleomorphism, high histological grade (poor differentiation), and absence of PgR. In univariate analysis of survival data, MT overexpression was a predictor of poor overall survival in the entire group of patients. In multivariate analysis, MT overexpression failed to be of prognostic significance, whereas classical histopathological parameters such as tumour size, histological grade, and PgR were of independent prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612258     DOI: 10.1111/j.1699-0463.1995.tb01107.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

Review 1.  Clinicopathological significance of metallothioneins in breast cancer.

Authors:  Rongxian Jin; Jingxiang Huang; Puay-Hoon Tan; Boon-Huat Bay
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

2.  Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer.

Authors:  R Jin; B H Bay; V T Chow; P H Tan; V C Lin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

3.  Potential role of p53 on metallothionein induction in human epithelial breast cancer cells.

Authors:  L Z Fan; M G Cherian
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

4.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 5.  Metallothioneins: Emerging Modulators in Immunity and Infection.

Authors:  Kavitha Subramanian Vignesh; George S Deepe
Journal:  Int J Mol Sci       Date:  2017-10-23       Impact factor: 5.923

6.  Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.

Authors:  Lei Wang; Fuli Xin; Nanping Lin; Yingchao Wang; Xiaolong Liu; Jingfeng Liu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.